Literature DB >> 21183785

Cytokinesis failure and attenuation: new findings in Fanconi anemia.

Philip J Mason1, Monica Bessler.   

Abstract

The hallmarks of the rare inherited disorder Fanconi anemia (FA) are progressive bone marrow failure and susceptibility to cancer. The former is the major cause of death for patients with FA, as it usually occurs earlier in life than cancer development. Despite spectacular advances in unraveling the molecular details of FA, the origin of the bone marrow failure that is central to this condition for most patients has long been puzzling and controversial. Two studies recently published in the JCI, including one in this issue, will add to the debate. They also highlight the fact that studying rare disorders can elucidate important new clinical and biological principles.

Entities:  

Mesh:

Year:  2010        PMID: 21183785      PMCID: PMC3007166          DOI: 10.1172/JCI45619

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.

Authors:  Y M Akkari; R L Bateman; C A Reifsteck; A D D'Andrea; S B Olson; M Grompe
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

2.  Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells.

Authors:  Patrizia Vinciguerra; Susana A Godinho; Kalindi Parmar; David Pellman; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

3.  Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance.

Authors:  J R Lo Ten Foe; M L Kwee; M A Rooimans; A B Oostra; A J Veerman; M van Weel; R M Pauli; N T Shahidi; I Dokal; I Roberts; C Altay; E Gluckman; R A Gibson; C G Mathew; F Arwert; H Joenje
Journal:  Eur J Hum Genet       Date:  1997 May-Jun       Impact factor: 4.246

Review 4.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

5.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

6.  Effect of caffeine in Fanconi anemia. I. Restoration of a normal duration of G2 phase.

Authors:  L Sabatier; B Dutrillaux
Journal:  Hum Genet       Date:  1988-07       Impact factor: 4.132

7.  The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability.

Authors:  Niall G Howlett; Toshiyasu Taniguchi; Sandra G Durkin; Alan D D'Andrea; Thomas W Glover
Journal:  Hum Mol Genet       Date:  2005-01-20       Impact factor: 6.150

8.  BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges.

Authors:  Kok-Lung Chan; Phillip S North; Ian D Hickson
Journal:  EMBO J       Date:  2007-06-28       Impact factor: 11.598

Review 9.  Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes.

Authors:  R Tiu; L Gondek; C O'Keefe; J P Maciejewski
Journal:  Leukemia       Date:  2007-06-07       Impact factor: 11.528

10.  Cancer incidence in persons with Fanconi anemia.

Authors:  Philip S Rosenberg; Mark H Greene; Blanche P Alter
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

View more
  1 in total

1.  PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients.

Authors:  Ming Li; Shanhu Li; Biao Liu; Meng-Meng Gu; Shitao Zou; Bei-Bei Xiao; Lan Yu; Wei-Qun Ding; Ping-Kun Zhou; Jundong Zhou; Zeng-Fu Shang
Journal:  J Exp Clin Cancer Res       Date:  2017-03-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.